<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="32173">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02687828</url>
  </required_header>
  <id_info>
    <org_study_id>P15-760</org_study_id>
    <nct_id>NCT02687828</nct_id>
  </id_info>
  <brief_title>A Prospective, Mono-Country and Multi-center Study to Observe Safety and Effectiveness of Adalimumab in KoREan Intestinal Behcet's Disease(BD) Patients</brief_title>
  <acronym>AMORE</acronym>
  <official_title>A Prospective, Mono-Country and Multi-center Study to Observe Safety and Effectiveness of Adalimumab in KoREan Intestinal Behcet's Disease(BD) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <brief_summary>
    <textblock>
      This study evaluates the safety profile and effectiveness of adalimumab in Korean intestinal
      Behcet's disease (BD) patients in routine clinical practice.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>From Day 1 to 70 days following 56 weeks from first dose of adalimumab or the last administration of adalimumab if the participant stopped receiving adalimumab before 56 weeks</time_frame>
    <description>All adverse events including serious and unexpected events will be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse drug reactions</measure>
    <time_frame>From Day 1 to 70 days following 56 weeks from first dose of adalimumab or the last administration of adalimumab if the participant stopped receiving adalimumab before 56 weeks</time_frame>
    <description>All adverse reactions including serious and unexpected reactions will be assessed.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Intestinal Behcet's Disease (BD)</condition>
  <arm_group>
    <arm_group_label>Subjects receiving adalimumab</arm_group_label>
    <description>The subjects who are prescribed adalimumab for intestinal Behcet's disease (BD) in accordance with the approved Korean label.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Intestinal Behcet's disease (BD) patients who are eligible to be prescribed adalimumab by
        the treating investigator as per Korean label will be enrolled.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be an adult &gt;= 19 years

          -  Subjects who are eligible to be treated with adalimumab for intestinal Behcet's
             disease in accordance with the approved label in Korea

          -  Subjects provide written authorization form for use/disclose of personal health data
             prior to participating in this study

        Exclusion Criteria:

          -  Subjects who are contraindicated to any anti-TNF agent

          -  Female subjects who are pregnant or breast feeding

          -  Subjects who are participating in other interventional clinical trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>EunJung Gu, MS</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyunjin Kim, BS</last_name>
    <phone>82-2-3429-9241</phone>
    <email>hkim@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>SuKyung Kim</last_name>
    <phone>82-2-3429-9235</phone>
    <email>sukyung.kim@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 147937</name>
      <address>
        <city>Daegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 147937, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 147933</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 147933, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 147936</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 147936, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 147932</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 147932, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 147934</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 147934, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 147935</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 147935, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 147938</name>
      <address>
        <city>Suwon-si</city>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 147938, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com/</url>
  </link>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 1, 2017</lastchanged_date>
  <firstreceived_date>February 17, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Adalimumab</keyword>
  <keyword>Effectiveness</keyword>
  <keyword>AMORE study</keyword>
  <keyword>Intestinal Behcet's disease (BD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Behcet Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
